Skip to main content

Advertisement

  • Research
  • Open Access

Phylogenetic identification of bacterial MazF toxin protein motifs among probiotic strains and foodborne pathogens and potential implications of engineered probiotic intervention in food

  • 1Email author,
  • 1,
  • 1,
  • 2 and
  • 1
Cell & Bioscience20122:39

https://doi.org/10.1186/2045-3701-2-39

©  Yan et al.; licensee BioMed Central Ltd. 2012

  • Received: 14 May 2012
  • Accepted: 10 October 2012
  • Published:

Abstract

Background

Toxin-antitoxin (TA) systems are commonly found in bacteria and Archaea, and it is the most common mechanism involved in bacterial programmed cell death or apoptosis. Recently, MazF, the toxin component of the toxin-antitoxin module, has been categorized as an endoribonuclease, or it may have a function similar to that of a RNA interference enzyme.

Results

In this paper, with comparative data and phylogenetic analyses, we are able to identify several potential MazF-conserved motifs in limited subsets of foodborne pathogens and probiotic strains and further provide a molecular basis for the development of engineered/synthetic probiotic strains for the mitigation of foodborne illnesses. Our findings also show that some probiotic strains, as fit as many bacterial foodborne pathogens, can be genetically categorized into three major groups based on phylogenetic analysis of MazF. In each group, potential functional motifs are conserved in phylogenetically distant species, including foodborne pathogens and probiotic strains.

Conclusion

These data provide important knowledge for the identification and computational prediction of functional motifs related to programmed cell death. Potential implications of these findings include the use of engineered probiotic interventions in food or use of a natural probiotic cocktail with specificity for controlling targeted foodborne pathogens.

Keywords

  • toxin-antitoxin module
  • probiotic cocktail
  • engineered probiotics
  • foodborne pathogens

Background

Foodborne illnesses continue to be an important public health concern in developing, as well as in developed countries, thus prevention of foodborne illness outbreaks through effective and novel interventions should be given priority. The U.S. Public Health Service has identified ten important foodborne pathogens causing human illnesses, including pathogenic strains of Escherichia coli, Salmonella, Listeria, Clostridium botulinum, Shigella, and Campylobacter, which are associated with more than 250 known foodborne diseases (http://www3.niaid.nih.gov/topics/foodborne/default.htm).

In addition, according to the World Health Organization (WHO), antibiotic overuse in food animal production is a major contributor to the emergence of antibiotic resistant foodborne pathogens [1]. The use of antibiotics in food animals for growth promotion and treatment disrupts the normal beneficial commensal bacterial microflora in the animal intestinal tract [2–6]. Recently, the human and chicken gut microbiome projects [7–12] have shed new light on the existence of a bacterial ‘phylogenetic core’ [13] consisting of a wide diversity of gastrointestinal bacteria by using new technologies such as next generation sequencing, 16S rRNA screens, metagenomics, and metaproteomics. Healthful, commensal bacteria found in the GI tract might be key members of known or potential probiotic strains revealed in this ‘phylogenetic core’, which may include Bacillus clausii, Bacillus pumilus, Lactobacillus acidophilus, Lactobacillus reuteri, Lactobacillus rhamnosus GG (ATCC 53103), Bifidobacterium infantis, Saccharomyces boulardii, Lactobacillus ruminis, Lactobacillus johnsonii str. NCC 533, and many others. These known probiotic strains have been used as dietary supplements, as treatments for illnesses caused by foodborne pathogens, and for disease prevention. Use of probiotic strains not only reduce invasion by bacterial pathogens, but also restore and maintain an optimal balance of healthy commensal bacteria in the human gut via production of antimicrobials [14–23].

One of the major mechanisms recognized as being responsible for apoptosis, or programmed cell death, and production of toxic metabolites in bacteria is through the regulation of a wide variety of bacterial toxin-antitoxin modules [24–26], such as MazE/MazF, a chromosomal toxin-antitoxin module [27–30], plasmid-encoded par D [31–33], chpBIK[26, 34], relBE[35, 36], and the PhoQ-PhoP system [37–40]. MazEF is one of the most well-studied toxin–antitoxin (TA) systems and has been found on the chromosomes of many bacteria. The MazF protein has been recently categorized as an endoribonuclease [41, 42] or as a type of RNA interference enzyme [43]. The link between this TA system and quorum sensing has also been explored recently through a small pentapeptide (NNWNN) called the Extracellular Death Factor (EDF) [44]. This small peptide motif (such as NNWNN) is known to be an extra-cellular death factor in E. coli and other bacterial species. The necessity of an “extracellular death factor” (EDF) or “cell death factor” (CDF) via MazEF-mediated cell death is a population phenomenon requiring the activation of quorum-sensing (cell-to-cell signaling) peptides in bacteria. High cell density was found to be associated with elevated concentrations of EDF, and the presence of EDF resulted in MazF-induced cell death [44]. From a food safety and public health perspective, use of EDF or a similar strategy may be used in place of antibiotics, resulting in less usage of antibiotics. We also noticed in one very interesting study that the induction of toxin MazF and the use of antibiotic share a similar mechanism by inhibiting the transcription and/or translation of the MazE antitoxin [45].

It has been theorized that there is “one toxin for one antitoxin” and interestingly MazF, in some bacteria, exhibits a selective inhibition of ribosomes and mRNAs [43, 46]. Numerous strains of probiotic bacteria, such as Lactobacillus spp., have been reported to produce antimicrobial agents [47], such as bacteriocins, that inhibit or kill closely-related species, or even different strains of the same species through the inhibition of transcription and translation by receptor binding. The antimicrobial activities of bacteriocins are due to a heterologous subgroup of ribosomally synthesized cationic peptides [48]. Nisin, a polycyclic antibacterial peptide 34 amino acid residues long, is one of the most studied bacteriocins and is produced by many strains of Lactococcus lactis. It has been approved by the FDA for use as a food preservative, and certain probiotic Lactobacillus strains have been thoroughly studied and evaluated in vitro and in vivo. For example, L. reuteri controls diarrhea in children and suppresses the growth and pathogenicity of harmful foodborne pathogens such as Salmonella, E. coli, Staphylococcus, and Listeria[49, 50]. L. casei GG has been used to treat Clostridium difficile infections and to reduce intestinal permeability [51–54]. L. reuteri is known to produce a broad-spectrum antimicrobial agent, reuterin, composed of the natural metabolic compound 3-hydroxypropionaldehyde, which has been used on the surface of sausages to inhibit growth of harmful bacteria and fungi [15, 16]. However, the molecular mechanisms underlying the effectiveness of individual probiotic strains have not been systematically studied and characterized. Several potential mechanisms of action, including their ability to generate diverse natural toxic metabolites, lactic acid, and other organic acids, enzymes, vitamins, and hydrogen peroxide, as well as antimicrobial peptides such as nisin, have been well-described [20].

The work reported herein explores the experimental antimicrobial possibilities and/or procedures for (1) expression of an engineered, stress-induced recombinant secreted fusion gene encoded by MazF and a small extracellular cell death factor (CDF) on the surface or extracellular space of recombinant probiotic bacteria or (2) for potential application of a cocktail of natural probiotic strains via experimental in vitro selection to control foodborne pathogens for improving the safety and quality of foods, as well as improving human health. The use of engineered probiotic strains or the natural probiotic cocktail consisting of mixed probiotic strain populations for targeting foodborne pathogens will potentially be able to selectively inactivate these pathogens, even in complex food matrices. Through gene/motif reshuffling [55, 56] and computational molecular modeling, this engineered and secreted bacterial fusion protein, MazF-CDF, which contains an enterokinase (EK) cleavage site [57–60] for releasing active CDF and MazF after protein secretion, should have a narrow range of applicability, limited to inactivating only specific foodborne pathogens such as E. coli O157, Salmonella, Listeria, Campylobacter, and potentially other human pathogens. This pathogen specificity is due to the fact that the genetically-engineered MazF-CDF fusion protein could be modified by the inclusion of specific genomic DNA sequences from various commensal, as well as pathogenic bacterial strains, identified through DNA/protein structure and functional comparisons. Additionally, this engineered antimicrobial polypeptide and MazF will be non-toxic to beneficial (healthful/probiotic) bacteria, as well as to its host that expresses the protein/peptide. Moreover, these engineered and secreted CDFs and MazF proteins/peptides can easily pass through infectious foodborne pathogen cell barriers mediating cell death, and thus could potentially reduce the use of deleterious compounds such as antibiotics or other harmful chemicals in the feed and food industry.

Results and discussion

General genetic analysis of probiotics and foodborne pathogen genomes

The genomic information from selected probiotic strains and foodborne pathogens is shown in Table 1. It revealed little diversity in genomic GC-content in the Bifidobacterium genus, while showing an astonishing diversity in the GC-content among Lactobacillus species, ranging from 33 to 51.5%. It has been demonstrated that genomic GC-content is correlated with a number of factors [61], including genome size [62] from species such as Lactobacillus, which ranges from 1.8 to 3.4 Mb in length. This demonstrates that the GC-content and genome size of Lactobacillus genomes may have implications related to the biological complexity and adaptation of this genus, and could be due to the rate of recombination that has been extensively studied in the E. coli genome [63]. Knowledge of genetic diversity is fundamental to development of synthetic probiotic genomes and/or nucleic acid sequence reshuffling strategies. In this paper, we demonstrate that the MazF protein is a suitable candidate for the determination of genetic relationships within sets of MazF proteins in combination with with functional motif analysis.
Table 1

Genomic information of selected microorganisms considered as potential probiotic strains and some major food-borne pathogens used in this study

Organism

Strain

Pathotype /or others

GenBank Accession /Assembly

GC (%)

Genome Size (~ Mb)

Campylobacter upsaliensis

JV21

pathogenic

ASM18534v1

NA

1.6

Lactobacillus coleohominis

101-4-CHN

probiotic

ASM16193v1

41.3

1.7

Campylobacter jejuni

RM1221

pathogenic

NC_003912.7

30.3

1.8

Lactobacillus johnsonii

FI9785

probiotic

NC_013504.1

34.4

1.8

Pediococcus pentosaceus

ATCC 25745

probiotic

CP000422.1

37.4

1.8

Streptococcus thermophilus LMG

LMG 18311

probiotic

NC_006448.1

39.1

1.8

Lactobacillus gasseri

ATCC 33323

probiotic

NC_008530.1

35.3

1.9

Lactobacillus sakei subsp. sakei

23K

probiotic

NC_007576.1

41.3

1.9

Lactobacillus delbrueckii subsp. bulgaricus

ATCC 11842

probiotic

NC_008054.1

49.7

1.9

Lactobacillus delbrueckii subsp. bulgaricus

ATCC BAA-365

probiotic

NC_008529.1

49.7

1.9

Leuconostoc citreum

KM20

probiotic

ASM2640v1

38.9

1.9

Bifidobacterium animalis subsp. Lactis

Bl-04

probiotic

NC_012814.1

60.5

1.9

Bifidobacterium animalis subsp. Lactis

DSM 10140

probiotic

NC_012815.1

60.5

1.9

Bifidobacterium animalis subsp. Lactis

AD011

probiotic

NC_011835.1

60.5

1.9

Lactobacillus amylovorus

GRL1118

probiotics

ASM19411v1

38.0

2.0

Lactobacillus johnsonii

NCC 533

probiotic

NC_005362.1

34.6

2.0

Lactobacillus acidophilus

NCFM

probiotic

NC_006814.3

34.7

2.0

Lactobacillus reuteri

DSM 20016

probiotic

NC_009513.1

38.9

2.0

Lactobacillus reuteri

JCM 1112

probiotic

NC_010609.1

38.9

2.0

Listeria monocytogenes

FSL J1-208

pathogenic

ASM16843v1

37.7

2.0

Lactobacillus salivarius

UCC118

probiotic

NC_007929.1

33

2.1

Lactobacillus helveticus

DPC 4571

probiotic

NC_010080.1

37.1

2.1

Leuconostoc mesenteroides subsp. mesenteroides

ATCC 8293

probiotic

NC_008531.1

37.7

2.1

Campylobacter concisus

13826

pathogenic

NC_009802.1

39.3

2.1

Lactobacillus fermentum

IFO 3956

probiotic

NC_010610.1

51.5

2.1

Bifidobacterium adolescentis

ATCC 15703

probiotic

NC_008618.1

59.2

2.1

Bifidobacterium bifidum

PRL2010

probiotic

NC_014638.1

Na

2.2

Bifidobacterium bifidum

S17

probiotic

NC_014616.1

Na

2.2

Lactobacillus amylovorus

GRL 1112

probiotic

NC_014724.1

Na

2.2

Lactobacillus brevis

ATCC 367

probiotic

NC_008497.1

46.1

2.3

Lactobacillus crispatus

CTV-05

probiotic

ASM16588v1

37.1

2.3

Bifidobacterium longum

NCC2705

probiotic

NC_004307.2

60.1

2.3

Bifidobacterium longum subsp. longum

BBMN68

probiotic

NC_014656.1

Na

2.3

Bifidobacterium longum subsp. infantis

157F

probiotic

NC_015052.1

Na

2.4

Bifidobacterium longum subsp. longum

JCM 1217

probiotic

NC_015067.1

Na

2.4

Lactococcus lactis subsp. lactis

Il1403

probiotic

NC_002662.1

35.3

2.4

Bifidobacterium longum

DJO10A

probiotic

NC_010816.1

60.2

2.4

Bifidobacterium longum subsp. longum

JDM301

probiotic

NC_014169.1

Na

2.5

Lactococcus lactis subsp. cremoris

MG1363

probiotic

NC_009004.1

35.7

2.5

Listeria grayi

DSM 20601

pathogenic

ASM14899v1*

41.6

2.6

Propionibacterium freudenreichii subsp. shermanii

CIRM-BIA1

probiotic

NC_014215.1

Na

2.6

Lactococcus lactis subsp. lactis

KF147

probiotic

NC_013656.1

34.9

2.6

Lactococcus lactis subsp. cremoris

SK11

probiotic

NC_008527.1

35.8

2.6

Bifidobacterium dentium

Bd1

probiotic

NC_013714.1

58.5

2.6

Bifidobacterium longum subsp. infantis

ATCC 15697

probiotic

NC_011593.1

59.9

2.8

Listeria monocytogenes

EGD-e

pathogenic

NC_003210.1

38

2.9

Lactobacillus casei str.

Zhang

probiotic

NC_014334.1

40.1

2.9

Lactobacillus casei

ATCC 334

probiotic

NC_008526.1

46.6

2.9

Lactobacillus paracasei subsp. paracasei

ATCC 25302

probiotic

ASM15949v1

46.5

2.9

Lactobacillus rhamnosus

GG

probiotic

NC_013198.1

46.7

3.0

Lactobacillus rhamnosus

Lc 705

probiotic

NC_013199.1

46.7

3.0

Lactobacillus casei

BL23

probiotic

NC_010999.1

46.3

3.1

Lactobacillus plantarum

JDM1

probiotic

NC_012984.1

44.7

3.2

Enterococcus faecalis

V583

probiotic

NC_004668.1

37.4

3.3

Lactobacillus plantarum

WCFS1

probiotic

NC_004567.1

44.4

3.3

Lactobacillus plantarum subsp. plantarum

ST-III

probiotic

NC_014554.1

Na

3.4

Bacillus selenitireducens

MLS10

Bio agent

ASM9308v1

48.7

3.6

Bacillus pumilus

SAFR-032

probiotic

NC_009848.1

41.3

3.7

Coprobacillus sp.

29_1

Non-pathogenic

Coprobacillus_sp_29_1_V1

NA

3.8

Vibrio cholerae

M66-2

pathogenic

NC_012578.1

47.6

3.9

Bacillus halodurans

C-125

Non-pathogenic

ASM1114v1

43.7

4.2

Bacillus amyloliquefaciens

Y2

probiotic

ASM28439v1

45.9

4.2

Clostridium difficile

630

pathogenic

NC_009089.1

29.1

4.3

Bacillus clausii

KSM-K16

probiotic

NC_006582.1

44.8

4.3

Shigella dysenteriae

Sd197

pathogenic

ASM1200v1]

50.9

4.6

Shigella flexneri

8401

pathogenic

NC_008258.1

50.9

4.6

Salmonella enterica subsp. arizonae serovar

RSK2980

pathogenic

NC_010067.1

51.4

4.6

Enterobacter sp.

638

pathogenic

NC_009436.1

52.9

4.7

Vibrio vulnificus

CMCP6

pathogenic

NC_004459.2

46.7

5.1

Escherichia coli

E24377A

pathogenic

NC_009801.1

50.6

5.2

Citrobacter rodentium

ICC168

pathogenic

NC_013716.1

54.6

5.4

Klebsiella variicola

At-22

pathogenic

NC_013850.1

57.6

5.5

Bacillus megaterium

QM B1551

probiotic

ASM2582v1

38.0

5.5

Escherichia coli O157:H7

Sakai

pathogenic

NC_002695.1

50.5

5.6

Bacillus thuringiensis serovar israelensis

ATCC 35646

Bio agents

ASM16769v1

35.0

5.9

Lachnospiraceae bacterium

3_1_57FAA_CT1

Non-pathogenic

Lach_bact_3_1_57FAA_CT1_V1

NA

7.7

*: assembly accession.

Ubiquitous existence of MazE/toxin, MazF

MazEF is a toxin-antitoxin (TA) module widely distributed among many bacterial species, including both foodborne pathogens and probiotic strains (Table 1, 2), such as Lactobacillus acidophilus, Lactobacillus reuteri, Lactobacillus rhamnosus GG (ATCC 53103), Escherichia coli, Selenomonas sputigena, Enterobacter spp., Campylobacter spp., Citrobacter spp., Thermoanaerobacter tengcongensis, Pelotomaculum thermopropionicum, Lactobacillus casei, Lactobacillus crispatus, Lactobacillus buchneri, Bifidobacterium longum subsp. infantis, Clostridium botulinum, Clostridium difficile, Vibrio spp., Listeria spp., Bacillus spp., Klebsiella variicola, and Salmonella enterica. Recent literature and computational analyses have shown the presence of many different types of TA modules in various localizations, e.g. some TA modules have been found within prophages, prophage-like elements, and other mobile genetic elements, such as plasmids [31–33]. Due to the existence of varying types of toxin-antitoxin modules and possible gene duplication events, in this paper we present the above one-to-one best matches of chromosomal-encoded mazF orthologs and homologs among 75 publically available genome sequences of foodborne pathogens and probiotic strains (Table 1), and the publically-available databases such as NCBI and the Uniprot database (http://www.uniprot.org/) in Table 2.
Table 2

The genetic characterization of the transcriptional modulator MazF , a chromosomal cell death factor from potential probiotic strains and some major food-borne pathogens used in this study

Organism

Type of organisms

Strains

Protein accession (GenBank)

Gene annotation

E. coli

Pathogen

EDL933

NP_289336.1

toxin ChpA

 

Pathogen

Sakai

NP_311669.1

 
 

Antibiotic resistance

B185

ZP_06660634.1*

 

Enterobacter sp.

pathogen

638

ABP60743.1*

transcriptional modulator of MazE/toxin, MazF

Shigella dysenteriae

pathogen

Sd197

YP_405833.1*

toxin ChpB

Citrobacter rodentium

pathogen

ICC168

YP_003366767.1*

Toxin component of the ChpB-ChpS toxin-antitoxin system

Vibrio vulnificus

pathogen

CECT4999=R99

YP_001393091.1*

growth inhibitor

Listeria welshimeri serovar 6b str.

pathogen

SLCC5334

YP_849071.1

PemK family transcriptional regulator

  

FSL J1-208

ZP_05296226.1*

PemK family transcriptional regulator

Listeria monocytogenes

 

SLCC3954

YP_003464028.1

transcriptional regulator, PemK family

  

FSL S4-120

ZP_07870171.1

toxin-antitoxin system, antitoxin component, MazF family

Listeria seeligeri serovar 1/2b str.

    

Listeria marthii

    

Listeria grayi

pathogen

DSM 20601

ZP_07054243.1*

MazF family toxin-antitoxin system protein

Clostridium difficile

pathogen

630

YP_001089981.1*

putative regulator of cell growth

  

QCD-66c26

ZP_05273557.1

putative regulator of cell growth

  

CIP 107932

ZP_05323891.1

putative regulator of cell growth

Klebsiella variicola

pathogen

At-22

YP_003438577.1*

transcriptional modulator of MazE/toxin, MazF pemK; protein PemK

  

1_1_55

ZP_06548086.1

 

Salmonella enterica subsp. arizonae serovar

pathogen

RSK2980

YP_001573441.1*

hypothetical protein SARI_04525

Campylobacter showae

pathogen

RM3277

ZP_05364729.1

addiction module antitoxin, RelB/DinJ family

Campylobacter concisus

pathogen

13826

YP_001466677.1

addiction module antitoxin

Campylobacter jejuni subsp.

pathogen

IA3902

ADC28395.1

prevent-host-death family protein

Campylobacter upsaliensis

pathogen

JV21

ZP_07894578.1*

ChpA/MazF transcriptional modulator

Shigella flexneri 2a str.

pathogen

301

NP_709188.1*

PemK protein

Shigella flexneri 5 str.

 

8401

YP_690766.1

growth inhibitor, PemK-like, autoregulated

Cronobacter sakazakii

pathogen

ATCC BAA-894

YP_001436394.1

bifunctional antitoxin/transcriptional repressor RelB

Lactobacillus coleohominis

probiotic

101-4-CHN

ZP_05553821.1*

regulatory protein

Bacillus megaterium

probiotic

QM B1551

YP_003560763.1*

endoribonuclease EndoA

  

DSM 319

YP_003595503.1

 

Bacillus thuringiensis serovar israelensis

probiotic

ATCC 35646

ZP_00740711.1*

MazF protein

  

KBAB4

YP_001643128.1

MazF protein

Bacillus weihenstephanensis

 

AH1134

ZP_03233130.1

PemK family

Bacillus cereus

    

Coprobacillus sp.

probiotic

29_1

ZP_08009764.1*

PemK family transcriptional regulator

Enterococcus faecalis

probiotic

V583

NP_814592.1

PemK family transcriptional regulator

  

TX0102

EFQ11602.1*

 
    

Toxin-antitoxin system, toxin compoment, MazF

  

TX2134

ZP_07557645.1*

 
    

Toxin-antitoxin system, toxin compoment, MazF

  

HH22

ZP_03985009.1

 
    

PemK family transcriptional regulator

Lactobacillus plantarum

probiotic

WCFS1

NP_786238.1*

cell growth regulatory protein

Lactobacillus rhamnosus

probiotic

LMS2-1

ZP_04441477.1*

cell growth regulatory protein

  

Lc 705

YP_003175134.1

transcriptional modulator of MazE/toxin, MazF

Lactobacillus johnsonii

probiotic

ATCC 33200

ZP_04007131.1*

PemK family growth inhibitor

Lactobacillus crispatus

probiotics

CTV-05

ZP_07789240.1*

ppGpp-regulated growth inhibitor

Lactobacillus gasseri

probiotic

ATCC 33323

YP_815460.1*

toxin-antitoxin system, toxin component, MazF family

  

224-1

ZP_06262236.1

 
  

MV-22

ZP_07711551.1

 

Lactobacillus casei

probiotic

BL23

YP_001986080.1

Cell growth regulatory protein

Lactobacillus amylovorus

probiotic

GRL1118

YP_005854914.1*

transcriptional modulator of MazE/toxin MazF

Vibrio cholerae

probiotic

1587

ZP_01950611.1*

transcriptional modulator of MazE/toxin, MazF

  

NCTC 8457

ZP_01969676.1

 

Pediococcus pentosaceus

probiotic

ATCC 25745

YP_805020.1*

toxin-antitoxin addiction module toxin component MazF (an endoRNAse)

Bacillus amyloliquefaciens

probiotic

Y2

YP_006327269.1*

Endoribonuclease

Bacillus pumilus

probiotic

SAFR-032

YP_001485694.1*

PemK family growth inhibitor endoribonuclease EndoA

  

ATCC 7061

ZP_03054587.1

 

Lactobacillus sakei subsp. sakai

probiotic

Sakei 23K

YP_396224.1

DNA-binding protein PemK family

Leuconostoc mesenteroides subsp. mesenteroides

probiotic

ATCC 8293

YP_819271.1*

toxin-antitoxin addiction module toxin component MazF

  

ATCC 19254

ZP_03913232.1

PemK family growth inhibitor

Leuconostoc mesenteroides subsp. cremoris

    

Enterococcus faecalis

probiotic

TX0102

EFQ11602.1*

toxin-antitoxin system, toxin component, MazF family

  

TX0031

EFT96737.1

 

Bifidobacterium animalis subsp. lactis

probiotic

HN019

ZP_02964075.1*

transcriptional modulator of MazE/toxin, MazF

Bifidobacterium bifidum

probiotic

NCIMB 41171

ZP_03645723.1

RelB antitoxin

Bifidobacterium longum subsp. longum

probiotic

JDM301

YP_003660624.1*

RelB antitoxin

  

DSM 20213

ZP_06596513.1

toxin-antitoxin system protein

Bifidobacterium breve

    

Bifidobacterium bifidum

probiotic

S17

YP_003938101.1

hypothetical protein with RelB antitoxin domain

Lactobacillus casei

Probiotic

ATCC 334

YP_807723.1

toxin-antitoxin addiction module toxin component MazF (an endoRNAse)

Lactobacillus casei

Probiotic

BL23

YP_001988635.1

Growth inhibitor

Lactobacillus paracasei subsp. paracasei

Probiotic

ATCC 25302

ZP_03963082.1*

PemK family transcriptional regulator

Lactobacillus casei str.

probiotic

Zhang

YP_003789562.1

toxin-antitoxin addiction module toxin component MazF

Lachnospiraceae bacterium

probiotic

3_1_57FAA_CT1

ZP_08609193.1*

hypothetical protein HMPREF0994_05199

Leuconostoc citreum

Probiotic

KM20

YP_001727503.1*

growth inhibitor

Lactobacillus reuteri

probiotic

DSM 20016

YP_001270863.1*

transcriptional modulator of MazE/toxin, MazF

  

JCM 1112

YP_001841242.1

hypothetical protein LAR_0246

  

MM2-3

ZP_03847756.1

PemK family growth inhibitor

Streptococcus sp. oral taxon 071 str.

probiotic

73H25AP

ZP_07458552.1*

ChpA/MazF transcriptional modulator

Bacillus selenitireducens

probiotic

MLS10

YP_003700699.1*

transcriptional modulator of MazE/toxin, MazF

Bacillus halodurans

probiotic

C-125

NP_244588.1*

ppGpp-regulated growth inhibitor (ChpA/MazF)

Enterococcus faecium

probiotic

DO

ZP_05714797.1*

PemK family protein

  

TX0133a04

ZP_07845579.1

toxin component, MazF family

  

TX0133C

ZP_07850444.1

toxin component, MazF family

*: data are presented in Figure 1.

Phylogenetic analyses and cluster analysis of MazF/antitoxin protein, a growth inhibitor

The phylogenetic tree in Figure 1 displays the phylogentic relationships of many well-recognized genera within Enterobacteriaceae, including several important foodborne pathogens such as pathogenic E. coli, Salmonella, Listeria, and Campylobacter, as well as some major probiotic strains. To build a phylogenetic tree from the data in Table 2, the amino acid sequences of all the MazF or growth inhibitor proteins were analyzed using the Geneious software package v5.5.7 with Neighbor-joining (NJ) method by applying ClustalW for sequence alignment (Figure 1). Three main clusters (viz., groups 1, 2, and 3) are given in Figure 1. At least two representatives of potential probiotic strains are listed for each group, depending on the complexity of groups. In group 1, the potential probiotic, non-pathogenic strains, such as Lactobacillus amylovorus, Lactobacillus crispatus, Streptococcus, Enterococcus faecium, Enterococcus, Lactobacillus plantarum, and Lactobacillus rhamnosus, are grouped with the foodborne pathogens E. coli, Vibrio vulnificus, and Vibrio cholerae. In group 2, the foodborne pathogens Enterobacter, Campylobacter upsaliensis, Klebsiella variicola, Salmonella enterica, Shigella flexneri, Shigella dysenteriae, and Citrobacter rodentium were shown to be genetically closer to Bacillus selenitireducens, Bacillus halodurans, and Enterococcus faecalis In group 3, some probiotic strains, such as the Bacillus, Lactobacillus, Leuconostoc, and the Bifidobacterium genera are categorized along with other major foodborne pathogens, such as Clostridium difficile, Listeria monocytogenes, Listeria grayi, and an emerging foodborne pathogen Pediococcus pentosaceus.
Figure 1
Figure 1

Phylogenetic analyses of Enterobacteriaceae based on MazF (toxin), a growth inhibitor. The NCBI accession numbers are shown after each taxon name.

Phylogenetic identification of bacterial toxin MazF protein motifs and the relationship between gene structure and phylogenetic classification

In Figure 2, it is shown that the number of candidate motifs are slightly different in each group, but with a high degree of amino acid sequence variability within conserved “hot spots” between groups 1, 2, and 3. To determine which motifs are the best candidates for the engineered MazF construction (discussed in next section) in each individual group, recent studies [43] suggest that the N-terminal (the first 80 amino acids in Figure 2) of the MazF protein are the most suitable motifs. The other motifs in the C-terminal might be referred to as ‘incorrect’ motifs. There are three criteria for evaluating the remaining motifs as “incorrect and without biological significance”, and this is related to: the mean hydrophobicity, identity, and the gene structure. In Figure 2, in the analysis for the phylogenetic identification of bacterial Toxin MazF protein motifs, the mean hydrophobicity sequence and identity were computed and compared for each sequence; it is interesting to find that all the compared MazF proteins have a higher degree of mean hydrophobicity, identity, and more conserved gene structure among several conserved amino acid regions, particular in the N-terminal. The selection of potential functional MazF motifs is discussed in the next section. The functional importance of the mean hydrophobicity has also been discussed to involve mRNA and protein degradation and slower translation of mRNA for disordered proteins (http://employees.csbsju.edu/hjakubowski/classes/ch331/protstructure/olprotfold.html).
Figure 2
Figure 2

ClustalW output (default settings) for the aligned amino acid sequences of MazF. The pdf images of the alignments were generated using Geneious v5.5.7. Conserved amino acids are highlighted in colors; the numbers (1 to 39) in this Figure correspond to the taxon names in Figure 1.

Bacterial probiotic cocktail strains

It is important to note that the benefits of probiotics are strain-specific [64, 65]. A commercial product, VSL#3, developed by Sigma-Tau Pharmaceuticals, Inc., provides a mixture of probiotic bacteria (B. breve, B. infantis, B. longum, L. acidophilus, L. bulgaricus, L. casei, L. plantarum, and Streptococcus thermophilus) to help protect GI tract integrity [66]. In this study, the bacterial probiotic cocktail strains we propose would be comprised of all representatives of groups 1, 2, and 3 shown in Figure 1. The principal basis behind the composition of these probiotic cocktail strains is the assumption that a combination of organisms might be more effective than the application of a single strain, which potentially could suppress many foodborne pathogens, such as the E. coli and vibros in Group 1, several foodborne pathogens, such as Enterobacter, Klebsiella variicola, Salmonella enterica, Shigella flexneri, Shigella dysenteriae, Citrobacter rodentium, and Campylobacter upsaliensis, (one of the most common Campylobacter strain found in people with diarrhea in Group 2), Clostridium difficile, Listeria monocytogenes, and Listeria grayi, in Group 3 of Figure 1. Table 1 shows an astonishing diversity in the genomic GC-content and genome size among Lactobacillus species and their diverse distribution in all groups within Figure 1, which indicates a potential to further identify other closely-related Lactobacillus species (not listed in Table 1) into the three previously-described groups. The hypothesis underlying our approach is that probiotic strains found within the same group with foodborne pathogens will have a reasonable degree of genetic and molecular phylogenetic compatibility and could bridge a relationship similar to a “symbiosis” of entities, including exchanging toxin/antitoxin molecules among the probiotic and pathogenic strains. Lactobacillus species are known to produce antimicrobial substances, including bacteriocins, lactic acid, and hydrogen peroxide. The MazEF toxin component may provide a basis for bacterial growth inhibition within the same group (Figure 1 and 2). Therefore, this toxin-antitoxin module may have great potential to inhibit the growth of potentially-pathogenic bacteria through a possible competitive exclusion due to selective inhibition [46]. Figures 1 and 2 list all possible cocktails of these probiotic strains. In reality, a foodborne outbreak is more likely to be associated with one particular foodborne pathogen in particular foods. For example, there is a low incidence of Campylobacter in ground beef and pork, while Campylobacter is the major foodborne pathogens associated with poultry, therefore, a single food-borne pathogen with the application of mixed probiotics will be considered initially.

Molecular recombination techniques: construction of genetically engineered synthetic probiotic strains

Figure 3 details an engineered probiotic strain bearing a recombinant plasmid containing a stress-induced promoter, followed by an in-frame gene fusion accomplished by fusing an appropriate signal peptide, a functional cell death peptide/factor (CDF), an enterokinase (EK) binding site, and a genetically-modified engineered MazF gene, which will be constructed and transformed into the probiotic bacteria. In this recombinant probiotic strain, environmental stress, relevant to food environments will trigger gene expression of this fusion protein under an environmental stress-inducible promoter. The signal peptide directs the encoded fusion protein to the extracellular space of the engineered probiotic strains. The signal peptide depleted fusion proteins will be cleaved by a biliary tract enterokinase directly into the digestive system to release the functionally-active CDF and MazF. This event will occur based on the ability of probiotic strains to form stable, non-infectious biofilm-type aggregates, which may attach with other bacteria, including foodborne pathogens, in the urogenital and intestinal tracts [22]. These active species-specific CDF and MazF proteins will bind and pass through “unfriendly” bacterial cell surface barriers into the cytoplasm. These processed CDFs and MazF proteins will selectively inactivate and/or inhibit proteins involved in cell survival and induce the synthesis of more cell death-related proteins with activity against foodborne pathogens, eventually controlling, inhibiting, or inactivating “unfriendly” cells. Although antitoxin MazE could reverse the bacteriocidal effect of the overexpressed MazF, MazE cannot impede the downstream cascade already initiated by MazF at early stages of the MazF-mediated cascade [42].
Figure 3
Figure 3

A Schematic representation of the engineered, secreted CDF and MazF -mediated cell death during food processing and storage. SP: promoter, CDF: cell death factor/peptide, EKB: enterokinase binding site.

The overall hypothesis for this experiment is graphically presented in Figure 3. The engineered MazF gene sequence will be designed based on the genomic sequences of all publically-available foodborne pathogenic strains by using reasoned random gene biosynthesis and/or genuine gene reshuffling to rapidly combine functions and properties of parental genes for the development of improved gene specificity and generality, molecular modeling (transcription factor binding site identification, etc.), and systems biology technologies/tools.

Conclusions

Survival of foodborne pathogens in cultures or in animal GI tracts may be very genus- or species-specific. Data presented in this paper can be explored to develop effective intervention strategies applied directly during food processing and preparation, as well as in the animal feed supply, which may lead to an overall reduction in use of antibiotic growth promoters (AGP) throughout the world. Recent research in molecular biology and genomics has provided potential applications of probiotic strains as dietary supplements, which could replace AGP in animal diets or as biotherapeutic agents in cases of antibiotic-associated diarrhea in travelers and in childhood diarrhea and other bacterial gastrointestinal illnesses. Experiments relating to this potential probiotic application may reveal a further greater range of potential benefits. For many of these potential benefits, current research is limited, and only preliminary results are available. All effects can only be attributed to the individual strain(s) tested. Testing of a specific supplement may not be extrapolated to benefits from any other strain of the same species, and testing results do not imply that comparable benefits will be imparted from other LAB (or other probiotics). In this study, we have computationally explored several potential intervention strategies to control foodborne pathogens, either by using a cocktail of probiotic strains or an engineered probiotic strain.

The inhibition of pathogens by probiotic strains is mainly due to the production of antibacterial peptides [67], the release of short-chain fatty acids, or reduction of the pH within the lumen [68, 69] by the production of organic acids or by decreasing pathogen adherence to intestinal epithelial cells [70]. Therefore, the benefits of probiotics could be very strain- or species-specific, and probiotic strains may rely on different mechanisms to suppress growth, attachment, or other metabolic processes, inherent to pathogenic bacteria. Moreover, the optimal effects of probiotic strains may involve the simultaneous use of more than one strain. Our contention in this paper is not experimental proof but, rather, a clear scientifically-backed hypothesis in the form of a detailed accompanying method that multi-probiotic strain composites with diverse genetic backgrounds may complement [71] one another as vectors of competitive exclusion and, therefore, could maximize the potential to inhibit an array of common foodborne pathogens [72] in the gastrointestinal tract of humans or livestock, as well as in foods and animal feed.

The use of probiotic bacteria with the ability to produce CDFs and engineered MazF to selectively inactivate pathogens is a novel approach to controlling pathogens in foods, and possibly treating human infections. A number of studies suggest that this project could have practical significance and be a potentially new approach for the development of novel and cost-effective food safety intervention technologies for the control of foodborne pathogens and improving public health [73–75].

The approaches described above represent a first attempt to describe a systematic approach or method to test the hypothesis that “friendly” bacteria can be used to inactivate or inhibit pathogens in food based on expression of MazF. There are many specific cell death factors that may be associated with bacterial programmed cell death and multi-cellular behavior mechanisms in foodborne pathogens. Through computational modeling, remodeling, genetic recombination, or further gene reshuffling, and exploring experimental approaches, it may be possible to evaluate and elucidate more effective CDFs and MazF to be used for controlling foodborne pathogens, which will ultimately result in a reduction in the use of antimicrobial compounds in humans and animals, as well as during food processing and storage.

Materials and methods

Genomic sequences

All of the genome and gene sequences examined in this study (Table 1 & 2) are available in GenBank (http://www.ncbi.nlm.nih.gov/genbank/GenbankOverview.html).

Identification and analysis of bacterial toxin-antitoxin modules, MazE/MazF

The prediction accuracy of the best chromosomal-encoded MazF orthologs among relatively distinct genome strains is critical for the performance of molecular phylogenetic analysis. We used a sequential BLAST workflow based on pairwise comparison by applying either an E. coli programmed cell death toxin MazF (Genbank accession: ZP_06660634.1), an endoribonuclease MazF, a MazF protein from Vibrio cholerae (ZP_01950611.1), or a PemK family transcriptional regulator protein (ZP_05296226.1) from Listeria monocytogenes to perform a BLASTP homology search of these combined protein sequences with all 75 publically available foodborne pathogen and probiotic strain genomic sequences (presented in Table 1) publically available databases such as NCBI and Uniprot database (http://www.uniprot.org/). BLAST search results were used to list MazF or MazF-like proteins from 75 different strains being represented as 39 different species (Table 2).

Phylogenetic analysis and computational identification of phylogenetic motifs of the MazF protein

In order to identify potential functional motifs of MazF proteins, phylogentic analyses of MazF proteins were conducted by applying the embedded multiple sequence alignment ClustalW program in the Geneious software package v 5.5.7 [76, 77] with the Neighbor Joining method. ClustalW output for the aligned amino acid sequences and the pdf images of the alignments were generated using the Geneious software package v 5.5.7.

Declarations

Acknowledgements

We express our appreciation to Dr. James Smith for his critical review of the manuscript. The mention of trade names or commercial products is solely for the purpose of providing specific information and does not imply recommendation or endorsement by the U.S. Department of Agriculture.

Authors’ Affiliations

(1)
Eastern Regional Research Center, Agricultural Research Service, U.S. Department of Agriculture, 600 E. Mermaid Lane, Wyndmoor, PA 19038, USA
(2)
Department of Mathematics and Computer Science, Franklin & Marshall College, P.O. Box 3003, Lancaster, PA 17604, USA

References

  1. Expert workshop on non-human antimicrobial usage and antimicrobial resistance. 2003,http://www.who.int/foodsafety/publications/micro/en/amr.pdf, GenevaGoogle Scholar
  2. Are antibacterial-containing products (soaps, household cleaners, etc.) better for preventing the spread of infection? Does their use add to the problem of resistance?. 2009, Antibiotic Resistance Questions & Answers, Centers for Disease Control and Prevention, AtlantaGoogle Scholar
  3. Ferber D: Antibiotic resistance. Livestock feed ban preserves drugs’ power. Science. 2002, 295: 27-28.PubMedGoogle Scholar
  4. Goossens H, Ferech M, Vander Stichele R, Elseviers M: Outpatient antibiotic use in Europe and association with resistance: a cross-national database study. Lancet. 2005, 365: 579-587.View ArticlePubMedGoogle Scholar
  5. Mathew AG, Cissell R, Liamthong S: Antibiotic resistance in bacteria associated with food animals: a United States perspective of livestock production. Foodborne Pathog Dis. 2007, 4: 115-133. 10.1089/fpd.2006.0066View ArticlePubMedGoogle Scholar
  6. WHO: Use of antimicrobials outside human medicine and resultant antimicrobial resistance in humans [R].:World Health Organization; 2002.http://www.who.int/mediacentre/factsheets/fs268/en/index.html.Google Scholar
  7. Ley RE, Backhed F, Turnbaugh P, Lozupone CA, Knight RD, Gordon JI: Obesity alters gut microbial ecology. Proc Natl Acad Sci U S A. 2005, 102: 11070-11075. 10.1073/pnas.0504978102PubMed CentralView ArticlePubMedGoogle Scholar
  8. Possemiers S, Grootaert C, Vermeiren J, Gross G, Marzorati M, Verstraete W, Van de Wiele T: The intestinal environment in health and disease - recent insights on the potential of intestinal bacteria to influence human health. Curr Pharm Des. 2009, 15: 2051-2065. 10.2174/138161209788489159View ArticlePubMedGoogle Scholar
  9. De Filippo C, Cavalieri D, Di Paola M, Ramazzotti M, Poullet JB, Massart S, Collini S, Pieraccini G, Lionetti P: Impact of diet in shaping gut microbiota revealed by a comparative study in children from Europe and rural Africa. Proc Natl Acad Sci U S A. 2010, 107: 14691-14696. 10.1073/pnas.1005963107PubMed CentralView ArticlePubMedGoogle Scholar
  10. Qu A, Brulc JM, Wilson MK, Law BF, Theoret JR, Joens LA, Konkel ME, Angly F, Dinsdale EA, Edwards RA, Nelson KE, White BA: Comparative metagenomics reveals host specific metavirulomes and horizontal gene transfer elements in the chicken cecum microbiome. PLoS One. 2008, 3: e2945. 10.1371/journal.pone.0002945PubMed CentralView ArticlePubMedGoogle Scholar
  11. Torok VA, Ophel-Keller K, Loo M, Hughes RJ: Application of methods for identifying broiler chicken gut bacterial species linked with increased energy metabolism. Appl Environ Microbiol. 2008, 74: 783-791. 10.1128/AEM.01384-07PubMed CentralView ArticlePubMedGoogle Scholar
  12. Turnbaugh PJ, Hamady M, Yatsunenko T, Cantarel BL, Duncan A, Ley RE, Sogin ML, Jones WJ, Roe BA, Affourtit JP, Egholm M, Henrissat B, Heath AC, Knight R, Gordon JI: A core gut microbiome in obese and lean twins. Nature. 2009, 457: 480-484. 10.1038/nature07540PubMed CentralView ArticlePubMedGoogle Scholar
  13. Tap J, Mondot S, Levenez F, Pelletier E, Caron C, Furet JP, Ugarte E, Munoz-Tamayo R, Paslier DL, Nalin R, Dore J, Leclerc M: Towards the human intestinal microbiota phylogenetic core. Environ Microbiol. 2009, 11: 2574-2584. 10.1111/j.1462-2920.2009.01982.xView ArticlePubMedGoogle Scholar
  14. Cabana MD, Shane AL, Chao C, Oliva-Hemker M: Probiotics in primary care pediatrics. Clin Pediatr (Phila). 2006, 45: 405-410. 10.1177/0009922806289614. 10.1177/0009922806289614View ArticleGoogle Scholar
  15. Cadieux P, Wind A, Sommer P, Schaefer L, Crowley K, Britton RA, Reid G: Evaluation of reuterin production in urogenital probiotic Lactobacillus reuteri RC-14. Appl Environ Microbiol. 2008, 74: 4645-4649. 10.1128/AEM.00139-08PubMed CentralView ArticlePubMedGoogle Scholar
  16. Cadieux PA, Burton J, Devillard E, Reid G: Lactobacillus by-products inhibit the growth and virulence of uropathogenic Escherichia coli. J Physiol Pharmacol. 2009, 60 (Suppl 6): 13-18.PubMedGoogle Scholar
  17. Canny GO, McCormick BA: Bacteria in the intestine, helpful residents or enemies from within?. Infect Immun. 2008, 76: 3360-3373. 10.1128/IAI.00187-08PubMed CentralView ArticlePubMedGoogle Scholar
  18. Gillor O, Etzion A, Riley MA: The dual role of bacteriocins as anti- and probiotics. Appl Microbiol Biotechnol. 2008, 81: 591-606. 10.1007/s00253-008-1726-5PubMed CentralView ArticlePubMedGoogle Scholar
  19. Lidbeck A, Edlund C, Gustafsson JA, Kager L, Nord CE: Impact of Lactobacillus acidophilus on the normal intestinal microflora after administration of two antimicrobial agents. Infection. 1988, 16: 329-336. 10.1007/BF01644541View ArticlePubMedGoogle Scholar
  20. Ng SC, Hart AL, Kamm MA, Stagg AJ, Knight SC: Mechanisms of action of probiotics: recent advances. Inflamm Bowel Dis. 2009, 15: 300-310. 10.1002/ibd.20602View ArticlePubMedGoogle Scholar
  21. Reid G, Bruce AW: Urogenital infections in women: can probiotics help?. Postgrad Med J. 2003, 79: 428-432. 10.1136/pmj.79.934.428PubMed CentralView ArticlePubMedGoogle Scholar
  22. Reid G, Jass J, Sebulsky MT, McCormick JK: Potential uses of probiotics in clinical practice. Clin Microbiol Rev. 2003, 16: 658-672. 10.1128/CMR.16.4.658-672.2003PubMed CentralView ArticlePubMedGoogle Scholar
  23. Reid G, Sanders ME, Gaskins HR, Gibson GR, Mercenier A, Rastall R, Roberfroid M, Rowland I, Cherbut C, Klaenhammer TR: New scientific paradigms for probiotics and prebiotics. J Clin Gastroenterol. 2003, 37: 105-118. 10.1097/00004836-200308000-00004View ArticlePubMedGoogle Scholar
  24. Grady R, Hayes F: Axe-Txe, a broad-spectrum proteic toxin-antitoxin system specified by a multidrug-resistant, clinical isolate of Enterococcus faecium. Mol Microbiol. 2003, 47: 1419-1432. 10.1046/j.1365-2958.2003.03387.xView ArticlePubMedGoogle Scholar
  25. Masuda Y, Miyakawa K, Nishimura Y, Ohtsubo E: chpA and chpB, Escherichia coli chromosomal homologs of the pem locus responsible for stable maintenance of plasmid R100. J Bacteriol. 1993, 175: 6850-6856.PubMed CentralPubMedGoogle Scholar
  26. Masuda Y, Ohtsubo E: Mapping and disruption of the chpB locus in Escherichia coli. J Bacteriol. 1994, 176: 5861-5863.PubMed CentralPubMedGoogle Scholar
  27. Gerdes K, Christensen SK, Lobner-Olesen A: Prokaryotic toxin-antitoxin stress response loci. Nat Rev Microbiol. 2005, 3: 371-382. 10.1038/nrmicro1147View ArticlePubMedGoogle Scholar
  28. Kolodkin-Gal I, Verdiger R, Shlosberg-Fedida A, Engelberg-Kulka H: A differential effect of E. coli toxin-antitoxin systems on cell death in liquid media and biofilm formation. PLoS One. 2009, 4: e6785. 10.1371/journal.pone.0006785PubMed CentralView ArticlePubMedGoogle Scholar
  29. Mittenhuber G: Occurrence of mazEF-like antitoxin/toxin systems in bacteria. J Mol Microbiol Biotechnol. 1999, 1: 295-302.PubMedGoogle Scholar
  30. Sat B, Hazan R, Fisher T, Khaner H, Glaser G, Engelberg-Kulka H: Programmed cell death in Escherichia coli: some antibiotics can trigger mazEF lethality. J Bacteriol. 2001, 183: 2041-2045. 10.1128/JB.183.6.2041-2045.2001PubMed CentralView ArticlePubMedGoogle Scholar
  31. Johnson EP, Strom AR, Helinski DR: Plasmid RK2 toxin protein ParE: purification and interaction with the ParD antitoxin protein. J Bacteriol. 1996, 178: 1420-1429.PubMed CentralPubMedGoogle Scholar
  32. Santos-Sierra S, Pardo-Abarrio C, Giraldo R, Diaz-Orejas R: Genetic identification of two functional regions in the antitoxin of the parD killer system of plasmid R1. FEMS Microbiol Lett. 2002, 206: 115-119. 10.1111/j.1574-6968.2002.tb10995.xView ArticlePubMedGoogle Scholar
  33. Sobecky PA, Easter CL, Bear PD, Helinski DR: Characterization of the stable maintenance properties of the par region of broad-host-range plasmid RK2. J Bacteriol. 1996, 178: 2086-2093.PubMed CentralPubMedGoogle Scholar
  34. Zhang Y, Zhu L, Zhang J, Inouye M: Characterization of ChpBK, an mRNA interferase from Escherichia coli. J Biol Chem. 2005, 280: 26080-26088. 10.1074/jbc.M502050200View ArticlePubMedGoogle Scholar
  35. Bech FW, Jorgensen ST, Diderichsen B, Karlstrom OH: Sequence of the relB transcription unit from Escherichia coli and identification of the relB gene. EMBO J. 1985, 4: 1059-1066.PubMed CentralPubMedGoogle Scholar
  36. Gotfredsen M, Gerdes K: The Escherichia coli relBE genes belong to a new toxin-antitoxin gene family. Mol Microbiol. 1998, 29: 1065-1076. 10.1046/j.1365-2958.1998.00993.xView ArticlePubMedGoogle Scholar
  37. Gunn JS, Miller SI: PhoP-PhoQ activates transcription of pmrAB, encoding a two-component regulatory system involved in Salmonella typhimurium antimicrobial peptide resistance. J Bacteriol. 1996, 178: 6857-6864.PubMed CentralPubMedGoogle Scholar
  38. Lippa AM, Goulian M: Feedback inhibition in the PhoQ/PhoP signaling system by a membrane peptide. PLoS Genet. 2009, 5: e1000788. 10.1371/journal.pgen.1000788PubMed CentralView ArticlePubMedGoogle Scholar
  39. Monsieurs P, De Keersmaecker S, Navarre WW, Bader MW, De Smet F, McClelland M, Fang FC, De Moor B, Vanderleyden J, Marchal K: Comparison of the PhoPQ regulon in Escherichia coli and Salmonella typhimurium. J Mol Evol. 2005, 60: 462-474. 10.1007/s00239-004-0212-7View ArticlePubMedGoogle Scholar
  40. Zwir I, Shin D, Kato A, Nishino K, Latifi T, Solomon F, Hare JM, Huang H, Groisman EA: Dissecting the PhoP regulatory network of Escherichia coli and Salmonella enterica. Proc Natl Acad Sci U S A. 2005, 102: 2862-2867. 10.1073/pnas.0408238102PubMed CentralView ArticlePubMedGoogle Scholar
  41. Amitai S, Kolodkin-Gal I, Hananya-Meltabashi M, Sacher A, Engelberg-Kulka H: Escherichia coli MazF leads to the simultaneous selective synthesis of both “death proteins” and “survival proteins”. PLoS Genet. 2009, 5 (3): e1000390. 10.1371/journal.pgen.1000390PubMed CentralView ArticlePubMedGoogle Scholar
  42. Amitai S, Yassin Y, Engelberg-Kulka H: MazF-mediated cell death in Escherichia coli: a point of no return. J Bacteriol. 2004, 186: 8295-8300. 10.1128/JB.186.24.8295-8300.2004PubMed CentralView ArticlePubMedGoogle Scholar
  43. Park JH, Yamaguchi Y, Inouye M: Intramolecular regulation of the sequence-specific mRNA interferase activity of MazF fused to a MazE fragment with a linker cleavable by specific proteases. Appl Environ Microbiol. 2012, 78 (11): 3794-3799. 10.1128/AEM.00364-12PubMed CentralView ArticlePubMedGoogle Scholar
  44. Belitsky M, Avshalom H, Erental A, Yelin I, Kumar S, London N, Sperber M, Schueler-Furman O, Engelberg-Kulka H: The Escherichia coli extracellular death factor EDF induces the endoribonucleolytic activities of the toxins MazF and ChpBK. Mol Cell. 2012, 41 (6): 625-635.View ArticleGoogle Scholar
  45. Engelberg-Kulka H, Sat B, Reches M, Amitai S, Hazan R: Bacterial programmed cell death systems as targets for antibiotics. Trends Microbiol. 2004, 12 (2): 66-71. 10.1016/j.tim.2003.12.008View ArticlePubMedGoogle Scholar
  46. Rothenbacher FP, Suzuki M, Hurley JM, Montville TJ, Kirn TJ, Ouyang M, Woychik NA: Clostridium difficile MazF toxin exhibits selective, not global, mRNA cleavage. J Bacteriol. 2012, 194 (13): 3464-3474. 10.1128/JB.00217-12PubMed CentralView ArticlePubMedGoogle Scholar
  47. Juneja VK, Dwivedi HP, Yan X: Novel natural food antimicrobials. Annu Rev Food Sci Technol. 2012, 3: 381-403. 10.1146/annurev-food-022811-101241View ArticlePubMedGoogle Scholar
  48. de Vuyst L, Vandamme E: Antimicrobial potential of lactic acid bacteria. In Bacteriocins of Lactic Acid Bacteria. Microbiology, Genetics and Applications. Edited by de Vuyst L, Vandamme EJ. London: Blackie Acad Prof; 1994:91–142.View ArticleGoogle Scholar
  49. Shornikova AV, Casas IA, Isolauri E, Mykkanen H, Vesikari T: Lactobacillus reuteri as a therapeutic agent in acute diarrhea in young children. J Pediatr Gastroenterol Nutr. 1997, 24: 399-404. 10.1097/00005176-199704000-00008View ArticlePubMedGoogle Scholar
  50. Williams MD, Ha CY, Ciorba MA: Probiotics as therapy in gastroenterology: a study of physician opinions and recommendations. J Clin Gastroenterol. 2010, 44: 631-636.PubMed CentralPubMedGoogle Scholar
  51. Goldin BR, Gorbach SL, Saxelin M, Barakat S, Gualtieri L, Salminen S: Survival of Lactobacillus species (strain GG) in human gastrointestinal tract. Dig Dis Sci. 1992, 37: 121-128. 10.1007/BF01308354View ArticlePubMedGoogle Scholar
  52. Plummer S, Weaver MA, Harris JC, Dee P, Hunter J: Clostridium difficile pilot study: effects of probiotic supplementation on the incidence of C. difficile diarrhoea. Int Microbiol. 2004, 7: 59-62.PubMedGoogle Scholar
  53. Vanderhoof JA, Whitney DB, Antonson DL, Hanner TL, Lupo JV, Young RJ: Lactobacillus GG in the prevention of antibiotic-associated diarrhea in children. J Pediatr. 1999, 135: 564-568. 10.1016/S0022-3476(99)70053-3View ArticlePubMedGoogle Scholar
  54. Vanderhoof JA, Young RJ: Current and potential uses of probiotics. Ann Allergy Asthma Immunol. 2004, 93: S33-S37. 10.1016/S1081-1206(10)61730-9View ArticlePubMedGoogle Scholar
  55. Arber W: Genetic variation: molecular mechanisms and impact on microbial evolution. FEMS Microbiol Rev. 2000, 24: 1-7. 10.1111/j.1574-6976.2000.tb00529.xView ArticlePubMedGoogle Scholar
  56. Saito H, Kashida S, Inoue T, Shiba K: The role of peptide motifs in the evolution of a protein network. Nucleic Acids Res. 2007, 35: 6357-6366. 10.1093/nar/gkm692PubMed CentralView ArticlePubMedGoogle Scholar
  57. Hadorn B, Steiner N, Sumida C, Peters TJ: Intestinal enterokinase. Mechanisms of tts “secretion” into the lumen of the small intestine. Lancet. 1971, 1: 165-166.View ArticlePubMedGoogle Scholar
  58. Kitamoto Y, Yuan X, Wu Q, McCourt DW, Sadler JE: Enterokinase, the initiator of intestinal digestion, is a mosaic protease composed of a distinctive assortment of domains. Proc Natl Acad Sci U S A. 1994, 91: 7588-7592. 10.1073/pnas.91.16.7588PubMed CentralView ArticlePubMedGoogle Scholar
  59. Song HW, Choi SI, Seong BL: Engineered recombinant enteropeptidase catalytic subunit: effect of N-terminal modification. Arch Biochem Biophys. 2002, 400: 1-6. 10.1006/abbi.2001.2737View ArticlePubMedGoogle Scholar
  60. Zhang Y, Vankemmelbeke MN, Holland LE, Walker DC, James R, Penfold CN: Investigating early events in receptor binding and translocation of colicin E9 using synchronized cell killing and proteolytic cleavage. J Bacteriol. 2008, 190: 4342-4350. 10.1128/JB.00047-08PubMed CentralView ArticlePubMedGoogle Scholar
  61. Hildebrand F, Meyer A, Eyre-Walker A: Evidence of Selection upon Genomic GC-Content in Bacteria. PLoS Genet. 2010, 6 (9): e1001107. 10.1371/journal.pgen.1001107PubMed CentralView ArticlePubMedGoogle Scholar
  62. Bentley SD, Parkhill J: Comparative genomic structure of prokaryotes. Annu Rev Genet. 2004, 38: 771-792. 10.1146/annurev.genet.38.072902.094318View ArticlePubMedGoogle Scholar
  63. Touchon M, Hoede C, Tenaillon O, Barbe V, Baeriswyl S, Bidet P, Bingen E, Bonacorsi S, Bouchier C, Bouvet O, Calteau A, Chiapello H, Clermont O, Cruveiller S, Danchin A, Diard M, Dossat C, Karoui ME, Frapy E, Garry L, Ghigo JM, Gilles AM, Johnson J, Le Bouguenec C, Lescat M, Mangenot S, Martinez-Jehanne V, Matic I, Nassif X, Oztas S, et al: Organised genome dynamics in the Escherichia coli species results in highly diverse adaptive paths. PLoS Genet. 2009, 5: e1000344. 10.1371/journal.pgen.1000344PubMed CentralView ArticlePubMedGoogle Scholar
  64. Canani RB, Cirillo P, Terrin G, Cesarano L, Spagnuolo MI, De Vincenzo A, Albano F, Passariello A, De Marco G, Manguso F, Guarino A: Probiotics for treatment of acute diarrhoea in children: randomised clinical trial of five different preparations. BMJ. 2007, 335: 340. 10.1136/bmj.39272.581736.55PubMed CentralView ArticlePubMedGoogle Scholar
  65. Weizman Z, Asli G, Alsheikh A: Effect of a probiotic infant formula on infections in child care centers: comparison of two probiotic agents. Pediatrics. 2005, 115: 5-9.PubMedGoogle Scholar
  66. Quigley EMM, Sanders ME: Probiotic foods for gastrointestinal health. Gastroenterology & Endoscopy News Special Edition. 2009, 7: 27-33.Google Scholar
  67. Corr SC, Gahan CG, Hill C: Impact of selected Lactobacillus and Bifidobacterium species on Listeria monocytogenes infection and the mucosal immune response. FEMS Immunol Med Microbiol. 2007, 50: 380-388. 10.1111/j.1574-695X.2007.00264.xView ArticlePubMedGoogle Scholar
  68. Marteau P, Seksik P: Tolerance of probiotics and prebiotics. J Clin Gastroenterol. 2004, 38: S67-S69. 10.1097/01.mcg.0000128929.37156.a7View ArticlePubMedGoogle Scholar
  69. Marteau P, Seksik P, Lepage P, Dore J: Cellular and physiological effects of probiotics and prebiotics. Mini Rev Med Chem. 2004, 4: 889-896. 10.2174/1389557043403369View ArticlePubMedGoogle Scholar
  70. Mack DR, Michail S, Wei S, McDougall L, Hollingsworth MA: Probiotics inhibit enteropathogenic E. coli adherence in vitro by inducing intestinal mucin gene expression. Am J Physiol. 1999, 276: G941-G950.PubMedGoogle Scholar
  71. Klaenhammer TR, Kullen MJ: Selection and design of probiotics. Int J Food Microbiol. 1999, 50: 45-57. 10.1016/S0168-1605(99)00076-8View ArticlePubMedGoogle Scholar
  72. Cursino L, Smajs D, Smarda J, Nardi RM, Nicoli JR, Chartone-Souza E, Nascimento AM: Exoproducts of the Escherichia coli strain H22 inhibiting some enteric pathogens both in vitro and in vivo. J Appl Microbiol. 2006, 100: 821-829. 10.1111/j.1365-2672.2006.02834.xView ArticlePubMedGoogle Scholar
  73. Iacono A, Raso GM, Canani RB, Calignano A, Meli R: Probiotics as an emerging therapeutic strategy to treat NAFLD: focus on molecular and biochemical mechanisms. J Nutr Biochem. 2010, 22: 699-711.View ArticleGoogle Scholar
  74. Lu TK, Collins JJ: Engineered bacteriophage targeting gene networks as adjuvants for antibiotic therapy. Proc Natl Acad Sci U S A. 2009, 106: 4629-4634. 10.1073/pnas.0800442106PubMed CentralView ArticlePubMedGoogle Scholar
  75. Westwater C, Kasman LM, Schofield DA, Werner PA, Dolan JW, Schmidt MG, Norris JS: Use of genetically engineered phage to deliver antimicrobial agents to bacteria: an alternative therapy for treatment of bacterial infections. Antimicrob Agents Chemother. 2003, 47: 1301-1307. 10.1128/AAC.47.4.1301-1307.2003PubMed CentralView ArticlePubMedGoogle Scholar
  76. Drummond A, Ashton B, Buxton S: Geneious v5.4. 2011, http://www.geneious.com,Google Scholar
  77. Kearse M, Moir R, Wilson A, Stones-Havas S, Cheung M, Sturrock S, Buxton S, Cooper A, Markowitz S, Duran C, et al: Geneious Basic: an integrated and extendable desktop software platform for the organization and analysis of sequence data. Bioinformatics. 2012, 28 (12): 1647-1649. 10.1093/bioinformatics/bts199PubMed CentralView ArticlePubMedGoogle Scholar

Copyright

© Yan et al.; licensee BioMed Central Ltd. 2012

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Advertisement

Cell & Bioscience

ISSN: 2045-3701

Contact us